… Corp. (NVDA) delivered the earnings report that Wall Street desperately … Last night, with its earnings report, Nvidia confirmed that the … past them Both revenue and earnings beat forecasts. As importantly, … for a dollar of Pfizer earnings than for a dollar …

… BNTX stock. In partnership with Pfizer, BNTX developed one of … year decline of about 19%, Pfizer reported. As a result, … transcript of its third-quarter earnings call) are BNT327 and … up disappointing the Street. Pfizer presumably has high-quality information …

… 2025 Valneva SE misses on earnings expectations. Reported EPS is $- … that is currently ongoing, Pfizer reconfirmed that they’re … VLA15, so we have Pfizer reconfirmed the regulatory submission … all timelines communicated by Pfizer do support that notion and …

… changing hands. It’s classic earnings reaction: good news hits, and … . Take UnitedHealth—when they beat earnings expectations a while back, shares … 5-10% in a day. Pfizer’s popped 15% or more … the flip side, not every earnings win sticks. Some healthcare names …

… We’re talking a fresh earnings report that smashed expectations, a … They also posted an adjusted earnings measure (that’s basically their … ve seen this movie before—earnings beats and big settlements … can cap the party. And Pfizer (PFE) mixed a vaccine sales …

… to start off on the earnings front. More big box retail … industries including Chevron, Qualcomm and Pfizer.

… several quarters, Nvidia enters earnings with sentiment under pressure … Nvidia's earnings Nvidia reports earnings on November 19 … expectations and beating earnings forecasts but trimming … (GD), Palantir Technologies (PLTR), Pfizer (PFE) and Qualcomm (QCOM …

Chiffre d’affaires de 127,0 millions d’euros contre 116,6 millions d’euros sur les neuf premiers mois de 2024 Trésorerie de 143,5 millions d’euros à fin septembre 2025 Flexibilité financière accrue grâce au succès du refinancement de la dette en octobre …

Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024 Cash and cash equivalents of €143.5 million at end of September 2025 Financial flexibility enhanced with successful debt refinancing in October 20251 Lyme disease …

Gesamtumsatz von 127,0 Millionen Euro gegenüber 116,6 Millionen Euro in den ersten neun Monaten des Jahres 2024 Liquide Mittel in Höhe von 143,5 Millionen Euro per Ende September 2025 Finanzielle Flexibilität durch erfolgreiche Refinanzierung im Oktober …